(67 days)
Not Found
Yes
The document explicitly states that the device uses an "artificial intelligence algorithm" and "deep learning techniques."
No
The device is a computer-aided triage and notification software that assists in workflow prioritization by flagging suspected cases for review; it does not directly treat or prevent a medical condition.
No
Explanation: The device is intended for workflow triage and notification, flagging suspected positive cases. It explicitly states it is "not intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out AAS or otherwise preclude clinical assessment." This indicates it assists in workflow, rather than providing a definitive diagnostic conclusion.
Yes
The device description explicitly states it is a "radiological computer-assisted triage and notification software system" and focuses solely on the software's function and performance. There is no mention of accompanying hardware components.
Based on the provided text, the EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM (EFAI AASCTA) is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the examination of specimens derived from the human body in order to provide information for diagnostic, monitoring, or compatibility purposes. This typically involves analyzing biological samples like blood, urine, tissue, etc.
- EFAI AASCTA's Function: The description clearly states that EFAI AASCTA is a radiological computer aided triage and notification software. It analyzes medical images (CTA scans), not biological specimens. Its purpose is to assist in workflow triage by flagging potential cases based on image analysis.
Therefore, EFAI AASCTA falls under the category of medical imaging software or a computer-aided detection/triage system, not an In Vitro Diagnostic device.
No
The letter does not state that the FDA has reviewed and approved or cleared a Predetermined Change Control Plan (PCCP) for this specific device. The "Control Plan Authorized (PCCP) and relevant text" section explicitly states "Not Found".
Intended Use / Indications for Use
EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM (EFAI AASCTA) is a radiological computer aided triage and notification software indicated for use in the analysis of chest-abdomen CTA in adults aged 22 and older. The device is intended to assist hospital networks and appropriately trained medical specialists in workflow triage by flagging and communicating suspected positive cases of aortic dissection (AD) or aortic intramural hematoma (IMH) pathology.
EFAI AASCTA uses an artificial intelligence algorithm to identify suspected findings. It makes case-level output available to a PACS/workstation for worklist prioritization or triage. EFAI AASCTA is not intended to direct attention to specific portions or anomalies of an image. Its results are not intended to be used on a stand-alone basis for clinical decisionmaking nor is it intended to rule out AAS or otherwise preclude clinical assessment of computed tomography cases.
Product codes (comma separated list FDA assigned to the subject device)
OAS, QAS
Device Description
EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM (EFAI AASCTA) is a radiological computer-assisted triage and notification software system. The software uses deep learning techniques to automatically analyze chest or chest-abdomen CTA and alerts the PACS/RIS workstation once images with features suggestive of AD or IMH are identified.
Through the use of EFAI AASCTA, a radiologist is able to review studies with features suggestive of AD or IMH earlier than in standard of care workflow.
The device is intended to provide a passive notification through the PACS/workstation to the radiologists indicating the existence of a case that may potentially benefit from the prioritization. It does not mark, highlight, or direct users' attention to a specific location on the original chest or chest-abdomen CTA. The device aims to aid in prioritization and triage of radiological medical images only.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
EFAI AASCTA uses an artificial intelligence algorithm to identify suspected findings.
The software uses deep learning techniques to automatically analyze chest or chest-abdomen CTA and alerts the PACS/RIS workstation once images with features suggestive of AD or IMH are identified.
Artificial intelligence algorithm with database of images
Input Imaging Modality
chest or chest-abdomen CTA
Anatomical Site
Chest or chest-abdomen, Chest and thoracoabdominal
Indicated Patient Age Range
adults aged 22 and older
Intended User / Care Setting
hospital networks and appropriately trained medical specialists
Description of the training set, sample size, data source, and annotation protocol
None of the studies was used as part of the EFAI AASCTA model development or analytical validation testing.
Description of the test set, sample size, data source, and annotation protocol
Ever Fortune.AI conducted a retrospective, blinded, multisite clinical validation study with the proposed device EFAI AASCTA with a pre-determined primary and secondary endpoint and performance goals to evaluate the performance of the EFAI AASCTA in identifying positive findings of aortic dissection (AD) or aortic intramural hematoma (IMH) from chest or chest-abdomen CTA scans on a validation dataset of 380 CTA studies (156 positives and 224 negatives) consecutively collected in the United States. None of the studies was used as part of the EFAI AASCTA model development or analytical validation testing.
The study population contained 51.58% females and 48.42% males, and the mean age of cases was 62.90 years. The CT scanner manufacturers of images were acquired from Philips, Toshiba, Siemens. GE, and others. Confounding cases in the dataset include possible confounders as follows: Artifact. Limited Field, Atherosclerotic Disease, Aortic Aneurysm, Arterial Dissection, and Vessel Disease.
The presence of AD or IMH in each case was determined independently by three U.S. board-certified radiologists, and the reference standard (ground truth) was generated by the majority agreement between the three experts.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
retrospective, blinded, multisite clinical validation study, 380 CTA studies (156 positives and 224 negatives), The EFAI AASCTA was able to demonstrate sensitivity and specificity of 0.929 (95% CI=0.878-0.960) and 0.915 (95% CI=0.871-0.945) respectively, which is substantially equivalent to the predicate device (BriefCase, K222329). The secondary endpoint of the observed system processing time per study is 37.86 seconds (95% CI=35.22-40.50) on average and was comparable with the predicate device (38 seconds).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity: 0.929 (95% CI=0.878-0.960)
Specificity: 0.915 (95% CI=0.871-0.945)
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.2080 Radiological computer aided triage and notification software.
(a)
Identification. Radiological computer aided triage and notification software is an image processing prescription device intended to aid in prioritization and triage of radiological medical images. The device notifies a designated list of clinicians of the availability of time sensitive radiological medical images for review based on computer aided image analysis of those images performed by the device. The device does not mark, highlight, or direct users' attention to a specific location in the original image. The device does not remove cases from a reading queue. The device operates in parallel with the standard of care, which remains the default option for all cases.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Design verification and validation must include:
(i) A detailed description of the notification and triage algorithms and all underlying image analysis algorithms including, but not limited to, a detailed description of the algorithm inputs and outputs, each major component or block, how the algorithm affects or relates to clinical practice or patient care, and any algorithm limitations.
(ii) A detailed description of pre-specified performance testing protocols and dataset(s) used to assess whether the device will provide effective triage (
e.g., improved time to review of prioritized images for pre-specified clinicians).(iii) Results from performance testing that demonstrate that the device will provide effective triage. The performance assessment must be based on an appropriate measure to estimate the clinical effectiveness. The test dataset must contain sufficient numbers of cases from important cohorts (
e.g., subsets defined by clinically relevant confounders, effect modifiers, associated diseases, and subsets defined by image acquisition characteristics) such that the performance estimates and confidence intervals for these individual subsets can be characterized with the device for the intended use population and imaging equipment.(iv) Stand-alone performance testing protocols and results of the device.
(v) Appropriate software documentation (
e.g., device hazard analysis; software requirements specification document; software design specification document; traceability analysis; description of verification and validation activities including system level test protocol, pass/fail criteria, and results).(2) Labeling must include the following:
(i) A detailed description of the patient population for which the device is indicated for use;
(ii) A detailed description of the intended user and user training that addresses appropriate use protocols for the device;
(iii) Discussion of warnings, precautions, and limitations must include situations in which the device may fail or may not operate at its expected performance level (
e.g., poor image quality for certain subpopulations), as applicable;(iv) A detailed description of compatible imaging hardware, imaging protocols, and requirements for input images;
(v) Device operating instructions; and
(vi) A detailed summary of the performance testing, including: test methods, dataset characteristics, triage effectiveness (
e.g., improved time to review of prioritized images for pre-specified clinicians), diagnostic accuracy of algorithms informing triage decision, and results with associated statistical uncertainty (e.g., confidence intervals), including a summary of subanalyses on case distributions stratified by relevant confounders, such as lesion and organ characteristics, disease stages, and imaging equipment.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left side of the logo is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
April 8, 2024
Ever Fortune.AI, Co., Ltd. Ti-Hao Wang Chief Technology Officer Rm. D, 8F. No. 573, Sec. 2 Taiwan Blvd. West Dist. Taichung City, 403020, TAIWAN
Re: K240291
EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT Trade/Device Name: SYSTEM Regulation Number: 21 CFR 892.2080 Regulation Name: Radiological Computer Aided Triage And Notification Software Regulatory Class: Class II Product Code: OAS Dated: January 31, 2024 Received: February 1, 2024
Dear Ti-Hao Wang:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrb/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
1
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Samul for
Jessica Lamb, Ph.D Assistant Director Imaging Software Team DHT8B: Division of Radiological Imaging Devices and Electronic Products OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
2
Indications for Use
510(k) Number (if known) K240291
Device Name EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM
Indications for Use (Describe)
EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM (EFAI AASCTA) is a radiological computer aided triage and notification software indicated for use in the analysis of chest-abdomen CTA in adults aged 22 and older. The device is intended to assist hospital networks and appropriately trained medical specialists in workflow triage by flagging and communicating suspected positive cases of aortic dissection (AD) or aortic intramural hematoma (IMH) pathology.
EFAI AASCTA uses an artificial intelligence algorithm to identify suspected findings. It makes case-level output available to a PACS/workstation for worklist prioritization or triage. EFAI AASCTA is not intended to direct attention to specific portions or anomalies of an image. Its results are not intended to be used on a stand-alone basis for clinical decisionmaking nor is it intended to rule out AAS or otherwise preclude clinical assessment of computed tomography cases.
Type of Use (Select one or both, as applicable)
| X Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.
3
Image /page/3/Picture/0 description: The image shows the logo for Ever Fortune AI. The logo consists of a stylized human figure in teal with a green circle containing a network of white dots as the head. To the right of the figure, the words "EVER" are stacked above "FORTUNE.AI" in teal. The "O" in "FORTUNE" is replaced with a smaller version of the green circle with white dots.
510(k) Summary
General Information 1.
| 510(k) Sponsor | Ever Fortune.AI Co., Ltd. |
|---|---|
| Address | Rm. D, 8F. No. 573, Sec. 2 Taiwan Blvd. |
| West Dist. | |
| Taichung City 403020 | |
| TAIWAN | |
| Applicant | Joseph Chang |
| Contact Information | 886-04-23213838 #216 |
| joseph.chang@everfortune.ai | |
| Correspondence Person | Ti-Hao Wang |
| Contact Information | 886-04-23213838 #168 |
| thothwang@gmail.com | |
| tihao.wang@everfortune.ai | |
| Date Prepared | January, 2024 |
2. Proposed Device
| Proprietary Name | EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME
ASSESSMENT SYSTEM |
|---------------------|-----------------------------------------------------------------|
| Common Name | EFAI AASCTA |
| Classification Name | Radiological computer aided triage and notification software |
| Regulation Number | 21 CFR 892.2080 |
| Product Code | QAS |
| Regulatory Class | II |
3. Predicate Device
| Proprietary Name | BriefCase |
|---|---|
| Premarket Notification | K222329 |
| Classification Name | Radiological computer aided triage and notification software |
| Regulation Number | 21 CFR 892.2080 |
| Product Code | QAS |
| Regulatory Class | II |
4
Image /page/4/Picture/0 description: The image shows the logo for Ever Fortune AI. The logo consists of a stylized human figure in teal with a green globe with a network pattern on top of the head. To the right of the figure is the text "EVER" in a larger teal font, with "FORTUNE.AI" in a smaller teal font below it.
Device Description 4.
EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM (EFAI AASCTA) is a radiological computer-assisted triage and notification software system. The software uses deep learning techniques to automatically analyze chest or chest-abdomen CTA and alerts the PACS/RIS workstation once images with features suggestive of AD or IMH are identified.
Through the use of EFAI AASCTA, a radiologist is able to review studies with features suggestive of AD or IMH earlier than in standard of care workflow.
The device is intended to provide a passive notification through the PACS/workstation to the radiologists indicating the existence of a case that may potentially benefit from the prioritization. It does not mark, highlight, or direct users' attention to a specific location on the original chest or chest-abdomen CTA. The device aims to aid in prioritization and triage of radiological medical images only.
ട. Intended Use / Indications for Use
EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM (EFAI AASCTA) is a radiological computer aided triage and notification software indicated for use in the analysis of chest or chest-abdomen CTA in adults aged 22 and older. The device is intended to assist hospital networks and appropriately trained medical specialists in workflow triage by flagging and communicating suspected positive cases of aortic dissection (AD) or aortic intramural hematoma (IMH) pathology.
EFAI AASCTA uses an artificial intelligence algorithm to identify suspected findings. It makes case-level output available to a PACS/workstation for worklist prioritization or triage. EFAI AASCTA is not intended to direct attention to specific portions or anomalies of an image. Its results are not intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out AAS or otherwise preclude clinical assessment of computed tomography angiography cases.
Comparison of Technological Characteristics with Predicate Device 6.
| Feature/
Function | Proposed Device:
EFAI AASCTA
(K240291) | Predicate Device:
BriefCase
(K222329) |
|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended
Use/Indication
for Use | EFAI CARDIOSUITE CTA
ACUTE AORTIC SYNDROME
ASSESSMENT SYSTEM (EFAI | BriefCase is a radiological
computer-aided triage and notification
software indicated for use in the analysis |
| | AASCTA) is a radiological
computer aided triage and
notification software indicated for
use in the analysis of chest or
chest-abdomen CTA in adults aged
22 and older. The device is
intended to assist hospital networks
and appropriately trained medical
specialists in workflow triage by
flagging and communicating
suspected positive cases of aortic
dissection (AD) or aortic intramural
hematoma (IMH) pathology.
EFAI AASCTA uses an artificial
intelligence algorithm to identify
suspected findings. It makes
case-level output available to a
PACS/workstation for worklist
prioritization or triage. EFAI
AASCTA is not intended to direct
attention to specific portions or
anomalies of an image. Its results
are not intended to be used on a
stand-alone basis for clinical
decision-making nor is it intended
to rule out AAS or otherwise
preclude clinical assessment of
computed tomography angiography
cases. | of CT exams with contrast (CTA and CT
with contrast) that include the chest in
adults or transitional adolescents aged 18
and older. The device is intended to assist
hospital networks and appropriately
trained medical specialists in workflow
triage by flagging and communicating
suspected positive cases of aortic
dissection (AD) pathology. BriefCase
uses an artificial intelligence algorithm to
analyze images and highlight cases with
detected findings on a standalone
application in parallel to the ongoing
standard of care image interpretation. The
user is presented with notifications for
cases with suspected findings.
Notifications include compressed
preview images that are meant for
informational purposes only and not
intended for diagnostic use beyond
notification. The device does not alter the
original medical image and is not
intended to be used as a diagnostic
device. The results of BriefCase are
intended to be used in conjunction with
other patient information and based on
the user's professional judgment, to assist
with triage/prioritization of medical
images. Notified clinicians are
responsible for viewing full images per
the standard of care. |
| User population | Hospital
networks
and
appropriately
trained
medical
specialists | Hospital networks and appropriately
trained medical specialists |
| Anatomical
region of interest | Chest and thoracoabdominal | Chest, abdomen and thoracoabdominal |
| Data acquisition
protocol | chest or chest-abdomen CTA | CT exams with contrast (CTA and CT
with contrast) that include the chest |
| Notification-only
(notification
alerts), parallel
workflow tool | Yes | Yes |
| Images
format | DICOM | DICOM |
| Interference with
standard
workflow | No | No |
| Algorithm | Artificial intelligence algorithm with database of images | Artificial intelligence algorithm with database of images |
EFAI AASCTA Traditional 510(k)
5
Image /page/5/Picture/0 description: The image shows the logo for Ever Fortune AI. The logo consists of a stylized figure with a circular head and a teal body. The head is green and has a network of white lines and dots, suggesting a connection or network. To the right of the figure, the text "EVER" is stacked above "FORTUNE.AI", both in a teal color that matches the body of the figure.
6
Image /page/6/Picture/0 description: The image shows a logo for a company called EVER FORTUNE.AI. The logo features a stylized human figure in teal, with a green globe-like shape with interconnected nodes as the head. The text "EVER FORTUNE.AI" is written in teal to the right of the figure, with the word "FORTUNE" having a similar globe-like shape in place of the letter "O".
7. Performance Data
Performance of the EFAI AASCTA has been evaluated and verified in accordance with software specifications and applicable performance standards through software verification and validation testing. Additionally, the software validation activities were performed in accordance with IEC 62304:2006/A1:2016 - Medical device software - Software life cycle processes, in addition to the FDA Guidance documents, "Content of Premarket Submissions for Device Software Functions" and "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions."
Ever Fortune.AI conducted a retrospective, blinded, multisite clinical validation study with the proposed device EFAI AASCTA with a pre-determined primary and secondary endpoint and performance goals to evaluate the performance of the EFAI AASCTA in identifying positive findings of aortic dissection (AD) or aortic intramural hematoma (IMH) from chest or chest-abdomen CTA scans on a validation dataset of 380 CTA studies (156 positives and 224 negatives) consecutively collected in the United States. None of the studies was used as part of the EFAI AASCTA model development or analytical validation testing.
The study population contained 51.58% females and 48.42% males, and the mean age of cases was 62.90 years. The CT scanner manufacturers of images were acquired from Philips, Toshiba, Siemens. GE, and others. Confounding cases in the dataset include possible confounders as follows: Artifact. Limited Field, Atherosclerotic Disease, Aortic Aneurysm, Arterial Dissection, and Vessel Disease.
The presence of AD or IMH in each case was determined independently by three U.S. board-certified radiologists, and the reference standard (ground truth) was generated by the majority agreement between the three experts. The performance criteria were set such that the lower bounds of 95% confidence intervals (Cls) of both sensitivity and specificity should exceed 0.8.
The observed results of the standalone performance validation study demonstrated that EFAI AASCTA by itself, in the absence of any interaction with a clinician, can provide case-level notifications with features suggestive of positive findings (AD or IMH) with satisfactory results. The EFAI AASCTA was able to demonstrate sensitivity and specificity of 0.929 (95% CI=0.878-0.960) and 0.915 (95% CI=0.871-0.945) respectively, which is substantially equivalent to the predicate device (BriefCase, K222329). The secondary endpoint of the observed system processing time per study is 37.86 seconds (95% CI=35.22-40.50) on average and was comparable with the predicate device (38 seconds).
7
Image /page/7/Picture/0 description: The image contains a logo for a company called "EVER FORTUNE.AI". The logo consists of a stylized figure with a circular head and a body that resembles a "T". The head is green and has a network-like pattern on it, while the body is teal. To the right of the figure, the company name is written in teal, with "EVER" on the top line and "FORTUNE.AI" on the bottom line.
In addition, the results of the subgroup analysis, which included different genders, age groups. CT manufacturer groups, and CT slice thickness groups, demonstrated that EFAI AASCTA consistently performed high performance, underscoring its reliability and effectiveness across diverse subgroups. We also evaluated the device's performance in cases with image quality issues (including Artifact and Limited Field) and accompanying radiologic findings (including Atherosclerotic Disease, Aortic Aneurysm, Arterial Dissection, and Vessel Disease) to assess the impact of these potential confounders. The device consistently performed reliably across these circumstances. Furthermore, our analysis of the device's ability to identify specific characteristics of positive findings, including their type, Stanford classification, and location, revealed that EFAI AASCTA maintains stable performance. In conclusion, the results demonstrate that the EFAI AASCTA device is determined to be substantially equivalent in safety and effectiveness to the predicate device. BriefCase.
8. Safety & Effectiveness
EFAI AASCTA has been designed, verified and validated in compliance with 21 CFR, Part 820.30 requirements. The device has been designed to meet the requirements associated with ISO 14971:2019 Medical devices - Application of risk management to medical devices. The EFAI AASCTA performance has been validated using retrospective data from case data and through the use of Reader comparison analysis.
9. Conclusion
Based on the information submitted in this premarket notification, and based on the indications for use, technological characteristics, and performance testing, the EFAI AASCTA raises no new questions of safety and effectiveness and is substantially equivalent to the predicate device in terms of safety, efficacy, and performance.